Matthew Biegler
Stock Analyst at Oppenheimer
(1.78)
# 3,310
Out of 4,996 analysts
81
Total ratings
33.33%
Success rate
-9.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Initiates: Outperform | $23 | $11.70 | +96.58% | 1 | Sep 4, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $22 | $9.51 | +131.34% | 7 | Sep 3, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.66 | +381.93% | 4 | Aug 14, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Outperform | $32 → $30 | $8.93 | +235.95% | 2 | Jul 31, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $2.90 | +141.38% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.25 | +620.00% | 2 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $11.12 | +7.91% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $33.62 | +375.91% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $8.27 | +444.14% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $112.10 | +2.59% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $26.83 | +97.54% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $12.97 | +154.43% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.55 | +1,190.32% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $5.17 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $9.26 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $8.84 | +58.37% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $11.01 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.00 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $6.77 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.04 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.25 | - | 2 | Dec 22, 2022 |
BridgeBio Oncology Therapeutics
Sep 4, 2025
Initiates: Outperform
Price Target: $23
Current: $11.70
Upside: +96.58%
Olema Pharmaceuticals
Sep 3, 2025
Maintains: Outperform
Price Target: $22
Current: $9.51
Upside: +131.34%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.66
Upside: +381.93%
Nurix Therapeutics
Jul 31, 2025
Reiterates: Outperform
Price Target: $32 → $30
Current: $8.93
Upside: +235.95%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $2.90
Upside: +141.38%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.25
Upside: +620.00%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $11.12
Upside: +7.91%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $33.62
Upside: +375.91%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $8.27
Upside: +444.14%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $112.10
Upside: +2.59%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $26.83
Upside: +97.54%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $12.97
Upside: +154.43%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.55
Upside: +1,190.32%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $5.17
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $9.26
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $8.84
Upside: +58.37%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $11.01
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.00
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $6.77
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.04
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.25
Upside: -